Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar Sells 53,735 Shares of Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Director Karimah Es Sabar sold 53,735 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $31.03, for a total value of $1,667,397.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Karimah Es Sabar also recently made the following trade(s):

• On Tuesday, March 31st, Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.17, for a total value of $1,848,365.05.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock opened at $32.11 on Friday. The company’s fifty day moving average price is $27.20 and its 200 day moving average price is $18.83. The stock has a market capitalization of $1.85 billion, a P/E ratio of -14.21 and a beta of 0.48. Capricor Therapeutics, Inc. has a 1 year low of $4.30 and a 1 year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Sell-side analysts predict that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on CAPR shares. B. Riley Financial lifted their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Oppenheimer lifted their price target on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Piper Sandler reissued an “overweight” rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. UBS Group set a $50.00 price objective on shares of Capricor Therapeutics in a report on Monday, December 15th. Finally, Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $46.09.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Capricor Therapeutics by 16.1% in the fourth quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after purchasing an additional 355,161 shares during the period. Suvretta Capital Management LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at $51,533,000. Tang Capital Management LLC purchased a new position in shares of Capricor Therapeutics during the 4th quarter worth $49,062,000. RA Capital Management L.P. purchased a new position in shares of Capricor Therapeutics during the 4th quarter worth $43,516,000. Finally, Geode Capital Management LLC increased its position in shares of Capricor Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock worth $29,367,000 after purchasing an additional 55,766 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.